Xenetic Biosciences, Inc. (NASDAQ:XBIO)

PRESS RELEASE

published on 07/23/2025 at 14:30, 8 months 1 day ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 8 months 16 days ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 8 months 16 days ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 8 months 16 days ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 10 months 10 days ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 10 months 10 days ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 10 months 10 days ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I
BRIEF

published on 04/09/2025 at 15:20, 11 months 15 days ago

Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting

Xenetic Biosciences Preclinical Data Solid Tumors DNase Technology CAR-T Cell Therapy
BRIEF

published on 04/09/2025 at 15:20, 11 months 15 days ago

Xenetic Biosciences partage des données précliniques prometteuses lors de la réunion du SITC

Biosciences Xénétiques Thérapie Cellulaire CAR-T Tumeurs Solides Données Précliniques Technologie DNase
PRESS RELEASE

published on 04/09/2025 at 15:15, 11 months 15 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website

Immuno-oncology Xenetic DNase I SITC 2025 CAR-T Cell Therapy

Published on 03/25/2026 at 04:50, 21 minutes ago

Arctic Fox Announces Closing of First Tranche of Non-Brokered Private Placement
Published on 03/24/2026 at 23:42, 5 hours 29 minutes ago

Presentation to Gold Coast Gold Conference
Published on 03/24/2026 at 23:00, 6 hours 11 minutes ago

Redwood AI Selected to Present at BIO-Europe Spring 2026, Europe's Largest Springtime Biotech Partnering Event
Published on 03/24/2026 at 18:55, 10 hours 16 minutes ago

Norse Gold Announces Closing of Private Placement Financing and Pending Reactivation on the TSX-V
Published on 03/24/2026 at 13:30, 15 hours 41 minutes ago

GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada

View all ACCESSWIRE

Published on 03/24/2026 at 21:08, 8 hours 3 minutes ago

Linedata Services: Linedata annonce le transfert de son contrat de liquidité auprès de Portzamparc (Groupe BNP Paribas)
Published on 03/24/2026 at 19:49, 9 hours 22 minutes ago

EEII AG: Cancellation of the Extraordinary General Meeting of March 26, 2026
Published on 03/24/2026 at 19:41, 9 hours 29 minutes ago

ASMALLWORLD Honoured with Regional Virtuoso Award in Continental Europe for “Most Engaged Member” in Recognition of Their Exceptional Contribution
Published on 03/24/2026 at 19:05, 10 hours 6 minutes ago

WBS Power Advances 3.2 GW Energy Infrastructure for Hyperscale Data Center Campus
Published on 03/24/2026 at 18:39, 10 hours 31 minutes ago

EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026

View all EQS

Published on 03/24/2026 at 18:21, 10 hours 50 minutes ago

Résultats annuels 2025
Published on 03/24/2026 at 18:21, 10 hours 50 minutes ago

2025 Annual results
Published on 03/24/2026 at 18:00, 11 hours 11 minutes ago

i2S : Résultats annuels 2025
Published on 03/24/2026 at 17:46, 11 hours 25 minutes ago

NRJ GROUP - Avis résultats annuels 2025
Published on 03/24/2026 at 17:46, 11 hours 25 minutes ago

NRJ GROUP - Press release annual results 2025

View all LES ECHOS COMFI WIRE

News